Jiabin Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jiabin Xu has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Mengting Li
Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research; Department of Pediatric Dentistry, College of Stomatology, Xi’an Jiaotong University
3 shared publications- Weijian Hu
Medical College, Northwest University, Xi’an 710127, China
3 shared publications - Xin Xie
College of Life Sciences, Northwest University, Xi’an 710127, China
3 shared publications Yameng Si
School of Stomatology, Xuzhou Medical University, Xuzhou, China
2 shared publications- Yameng Si
School of Stomatology, Xuzhou Medical University, Xuzhou 221004, China
2 shared publications Yuxuan Li
Department of Epidemiology and Biostatistics, School of Public Health, Xi’an Jiaotong University Health Science Center
2 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Frontiers Media SA in Frontiers in Education
- Vol. 11, 1956663
Educational outcomes associated with a project-driven offline–chairside–digital teaching model in undergraduate pediatric dentistry: a controlled quasi-experimental study
Background: Project-driven learning and digital technologies have become increasingly essential in dental education to bridge the gap between theoretical instruction and clinical practice. Traditional teaching in the comparator cohort relied primarily on lectures, laboratory simulation, and clinical observation, whereas the intervention cohort received an integrated project-driven model combining offline instruction, chairside clinical exposure, and digital workflows. This study aimed to evaluate the educational outcomes associated with this integrated teaching model in undergraduate pediatric dentistry. Methods: A controlled quasi-experimental study was conducted among 246 fourth-year dental students from the 2020–2021 cohorts at the Xi'an Jiaotong University, Air Force Military Medical University and Xuzhou Medical University. The 2020-entry cohort received traditional instruction in 2024 ( n = 121), whereas the 2021-entry cohort received the three-step teaching method in 2025 ( n = 125). The intervention incorporated two clinical projects involving digitally designed and 3D-printed space maintainers and metal splints. Course scores, clinical performance, self-reported proficiency, and student feedback were compared between cohorts. Results: The 2021 cohort achieved higher overall course grades (88 vs. 85) and a numerically more favorable grade distribution, with higher rates of “excellent” (13% vs. 7%) and “good” (45% vs. 42%) and lower “fail” (4% vs. 5%). Clinical skills performance improved across all five core procedures, with the most notable improvements in metal preformed crown restoration (excellent from 26% to 34%) and pulpectomy of primary teeth (fail from 5% to 1%). Student feedback indicated that the three-step method improved learning motivation, clinical confidence, and professional skills, while also identifying the need for more digital practice time and better equipment access. Conclusion: The project-driven offline–chairside–digital teaching model was associated with improved clinical performance, learning outcomes, and student engagement in undergraduate pediatric dentistry education. This approach may provide an effective framework for integrating project-based learning and digital dentistry within competency-based curricula.
- 30 September 2026
- Published by Frontiers Media SA in Frontiers in Education
- Vol. 11, 1956663
Open AccessEducational outcomes associated with a project-driven offline–chairside–digital teaching model in undergraduate pediatric dentistry: a controlled quasi-experimental study
Background: Project-driven learning and digital technologies have become increasingly essential in dental education to bridge the gap between theoretical instruction and clinical practice. Traditional teaching in the comparator cohort relied primarily on lectures, laboratory simulation, and clinical observation, whereas the intervention cohort received an integrated project-driven model combining offline instruction, chairside clinical exposure, and digital workflows. This study aimed to evaluate the educational outcomes associated with this integrated teaching model in undergraduate pediatric dentistry. Methods: A controlled quasi-experimental study was conducted among 246 fourth-year dental students from the 2020–2021 cohorts at the Xi'an Jiaotong University, Air Force Military Medical University and Xuzhou Medical University. The 2020-entry cohort received traditional instruction in 2024 ( n = 121), whereas the 2021-entry cohort received the three-step teaching method in 2025 ( n = 125). The intervention incorporated two clinical projects involving digitally designed and 3D-printed space maintainers and metal splints. Course scores, clinical performance, self-reported proficiency, and student feedback were compared between cohorts. Results: The 2021 cohort achieved higher overall course grades (88 vs. 85) and a numerically more favorable grade distribution, with higher rates of “excellent” (13% vs. 7%) and “good” (45% vs. 42%) and lower “fail” (4% vs. 5%). Clinical skills performance improved across all five core procedures, with the most notable improvements in metal preformed crown restoration (excellent from 26% to 34%) and pulpectomy of primary teeth (fail from 5% to 1%). Student feedback indicated that the three-step method improved learning motivation, clinical confidence, and professional skills, while also identifying the need for more digital practice time and better equipment access. Conclusion: The project-driven offline–chairside–digital teaching model was associated with improved clinical performance, learning outcomes, and student engagement in undergraduate pediatric dentistry education. This approach may provide an effective framework for integrating project-based learning and digital dentistry within competency-based curricula.
- Open Access
Plant-Derived Bioactive Ingredients for Osteoporosis and Bone Regeneration: Mechanisms, Pharmacology, and Delivery Strategies
Icariin (ICA), a prenylated flavonoid glycoside from Epimedium (Yin Yang Huo), exhibits multi-organ pharmacological effects and has emerged as a promising candidate for osteoporosis therapy and bone tissue regeneration because of its capacity to modulate diverse osteogenic, anti-inflammatory, and angiogenic signaling pathways. Preclinical studies in osteoporotic models suggest that ICA improves trabecular microarchitecture and increases bone mineral density. Mechanistically, ICA modulates bone remodeling bidirectionally: it promotes osteoblast differentiation and extracellular matrix mineralization via activation of pro-osteogenic pathways, including Wnt/β-catenin and PI3K/Akt signaling, while simultaneously inhibiting osteoclastogenesis and bone resorption by suppressing RANKL-mediated NF-κB activation, thus reestablishing remodeling equilibrium. Despite these benefits, clinical advancement is hindered by the suboptimal oral bioavailability of ICA, stemming from poor intestinal absorption and extensive first-pass metabolism. To address this, innovative delivery systems have been engineered to enhance localized bioavailability and sustain therapeutic efficacy, such as hydrogel depots, nanoparticle formulations, and 3D-printed scaffolds enabling precise, controlled release. In bone tissue engineering applications, ICA-incorporated biomaterials—either standalone or in combination with osteogenic factors or exosomes—foster a regenerative niche by mitigating inflammation and oxidative stress, while synergistically promoting osteogenesis and angiogenesis, thereby expediting bone defect healing and osseointegration. Overall, these mechanistic elucidations and delivery advancements underscore ICA’s potential as a translational candidate for osteoporosis treatment and bone regenerative therapies. This review aims to critically and systematically synthesize current evidence on ICA-mediated bone repair and regeneration, with a particular emphasis on the molecular regulation of osteogenic signaling, the restoration of bone-remodeling homeostasis, and delivery-system-enabled strategies that may facilitate translational application.
Open AccessPlant-Derived Bioactive Ingredients for Osteoporosis and Bone Regeneration: Mechanisms, Pharmacology, and Delivery Strategies
Icariin (ICA), a prenylated flavonoid glycoside from Epimedium (Yin Yang Huo), exhibits multi-organ pharmacological effects and has emerged as a promising candidate for osteoporosis therapy and bone tissue regeneration because of its capacity to modulate diverse osteogenic, anti-inflammatory, and angiogenic signaling pathways. Preclinical studies in osteoporotic models suggest that ICA improves trabecular microarchitecture and increases bone mineral density. Mechanistically, ICA modulates bone remodeling bidirectionally: it promotes osteoblast differentiation and extracellular matrix mineralization via activation of pro-osteogenic pathways, including Wnt/β-catenin and PI3K/Akt signaling, while simultaneously inhibiting osteoclastogenesis and bone resorption by suppressing RANKL-mediated NF-κB activation, thus reestablishing remodeling equilibrium. Despite these benefits, clinical advancement is hindered by the suboptimal oral bioavailability of ICA, stemming from poor intestinal absorption and extensive first-pass metabolism. To address this, innovative delivery systems have been engineered to enhance localized bioavailability and sustain therapeutic efficacy, such as hydrogel depots, nanoparticle formulations, and 3D-printed scaffolds enabling precise, controlled release. In bone tissue engineering applications, ICA-incorporated biomaterials—either standalone or in combination with osteogenic factors or exosomes—foster a regenerative niche by mitigating inflammation and oxidative stress, while synergistically promoting osteogenesis and angiogenesis, thereby expediting bone defect healing and osseointegration. Overall, these mechanistic elucidations and delivery advancements underscore ICA’s potential as a translational candidate for osteoporosis treatment and bone regenerative therapies. This review aims to critically and systematically synthesize current evidence on ICA-mediated bone repair and regeneration, with a particular emphasis on the molecular regulation of osteogenic signaling, the restoration of bone-remodeling homeostasis, and delivery-system-enabled strategies that may facilitate translational application.
- Open Access
- 20 February 2026
- Published by Springer Nature in BMC Geriatrics
- Vol. 26 (1)
Sensory drivers of dental fear in the older adults: a cross-age study based on an integrated Kano-IPA model
With the accelerating aging of society, oral health issues among older adults are becoming increasingly prominent. Dental fear (DF) is a significant psycho
- 20 February 2026
- Published by Springer Nature in BMC Geriatrics
- Vol. 26 (1)
Open AccessSensory drivers of dental fear in the older adults: a cross-age study based on an integrated Kano-IPA model
With the accelerating aging of society, oral health issues among older adults are becoming increasingly prominent. Dental fear (DF) is a significant psycho
- Open Access
- 6 February 2026
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
EXO-VNN2 derived from 3D-cultured DPSCs enhances the inflammatory response of PDLSCs and suppresses bone regeneration in periodontitis
As a chronic inflammatory disease characterized by periodontal tissue destruction, periodontitis has a pathogenesis that remains incompletely understood. T
- 6 February 2026
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
Open AccessEXO-VNN2 derived from 3D-cultured DPSCs enhances the inflammatory response of PDLSCs and suppresses bone regeneration in periodontitis
As a chronic inflammatory disease characterized by periodontal tissue destruction, periodontitis has a pathogenesis that remains incompletely understood. T
- 28 November 2025
- Published by Wiley in Orthodontics & Craniofacial Research
- Vol. 29 (2) , 225-236
Effect of Miniscrew Implant Anchorage in Orthodontic Orthognathic Treatment of Patients With Skeletal Class II Malocclusion
Objective: To compare the therapeutic efficacy of miniscrew implant anchorage with that of conventional extraoral arch anchorage, both of which are combined with orthodontic–orthognathic treatment, in patients with skeletal Class II malocclusion. Methods: This prospective nonrandomised controlled study included 130 patients. In terms of treatment method and patient preference, 58 patients received conventional orthodontic‐orthognathic treatment with extraoral arch anchorage (conventional group), whereas 72 patients received treatment augmented with miniscrew implant anchorage (study group). The treatment protocol for all patients followed the conventional three‐stage orthodontic–orthognathic approach. The outcomes assessed included treatment effectiveness, adverse events, root resorption (volume via CT), skeletal and dental changes (via comprehensive cephalometric analysis), soft tissue profile changes, facial aesthetics, and alveolar bone morphology (via CBCT). Results: The total effective rate was significantly greater in the study group (95.83%) than in the conventional group (74.14%) ( p < 0.05). While both groups presented significant root resorption posttreatment ( p < 0.05), the degree of resorption did not differ significantly between the groups ( p > 0.05). Crucially, CBCT analysis revealed significantly better preservation of the palatal bone plate and alveolar bone height in the study group ( p < 0.05). The study group also demonstrated significantly greater improvements in skeletal parameters (SNA, SNB, FMA, and PP‐FH), dental decompensation (U1‐SN, U1‐NA, L1‐MP, and L1‐NB), soft tissue indices, and facial aesthetics ( p < 0.05). The incidence of adverse events was significantly lower in the study group (34.72% vs. 75.86%, p < 0.05). Logistic analysis revealed that oral hygiene, vertical facial pattern, peri‐implant swelling, and force application time were independent risk factors for miniscrew success. Conclusion: The integration of miniscrew implant anchorage in orthodontic‐orthognathic treatment for skeletal Class II malocclusion provides superior clinical efficacy. Its primary advantage lies in enabling enhanced control over dental decompensation and skeletal correction, leading to significantly improved facial aesthetics, a more favorable mandibular position, and better alveolar bone preservation, with a lower complication profile. This represents an effective and reliable treatment option for these patients.
- 28 November 2025
- Published by Wiley in Orthodontics & Craniofacial Research
- Vol. 29 (2) , 225-236
Effect of Miniscrew Implant Anchorage in Orthodontic Orthognathic Treatment of Patients With Skeletal Class II Malocclusion
Objective: To compare the therapeutic efficacy of miniscrew implant anchorage with that of conventional extraoral arch anchorage, both of which are combined with orthodontic–orthognathic treatment, in patients with skeletal Class II malocclusion. Methods: This prospective nonrandomised controlled study included 130 patients. In terms of treatment method and patient preference, 58 patients received conventional orthodontic‐orthognathic treatment with extraoral arch anchorage (conventional group), whereas 72 patients received treatment augmented with miniscrew implant anchorage (study group). The treatment protocol for all patients followed the conventional three‐stage orthodontic–orthognathic approach. The outcomes assessed included treatment effectiveness, adverse events, root resorption (volume via CT), skeletal and dental changes (via comprehensive cephalometric analysis), soft tissue profile changes, facial aesthetics, and alveolar bone morphology (via CBCT). Results: The total effective rate was significantly greater in the study group (95.83%) than in the conventional group (74.14%) ( p < 0.05). While both groups presented significant root resorption posttreatment ( p < 0.05), the degree of resorption did not differ significantly between the groups ( p > 0.05). Crucially, CBCT analysis revealed significantly better preservation of the palatal bone plate and alveolar bone height in the study group ( p < 0.05). The study group also demonstrated significantly greater improvements in skeletal parameters (SNA, SNB, FMA, and PP‐FH), dental decompensation (U1‐SN, U1‐NA, L1‐MP, and L1‐NB), soft tissue indices, and facial aesthetics ( p < 0.05). The incidence of adverse events was significantly lower in the study group (34.72% vs. 75.86%, p < 0.05). Logistic analysis revealed that oral hygiene, vertical facial pattern, peri‐implant swelling, and force application time were independent risk factors for miniscrew success. Conclusion: The integration of miniscrew implant anchorage in orthodontic‐orthognathic treatment for skeletal Class II malocclusion provides superior clinical efficacy. Its primary advantage lies in enabling enhanced control over dental decompensation and skeletal correction, leading to significantly improved facial aesthetics, a more favorable mandibular position, and better alveolar bone preservation, with a lower complication profile. This represents an effective and reliable treatment option for these patients.
- Open Access
- 5 September 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (9) , 1338
Pharmacological Effects and Mechanisms of Tanshinone IIA in Bone Injury Repair
Tanshinone IIA (T-IIA), a fat-soluble diterpene quinone extracted from Salvia miltiorrhiza, is widely recognized for its multiple pharmacological properties, including anti-inflammatory, antioxidant, anti-fibrotic, and anti-tumor effects. Recent studies have highlighted its great potential in treating bone metabolic disorders, especially osteoporosis and bone damage repair. Bone health depends on the dynamic balance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption. Disruption of this balance can lead to diseases such as osteoporosis, which is often diagnosed after a fracture, seriously affecting the quality of life and increasing the medical burden. Early identification of high-risk groups and appropriate treatment are essential for preventing fracture recurrence. Studies have shown that T-IIA can promote osteoblast differentiation and inhibit osteoclast activity, targeting key signaling pathways such as NF-κB, PI3K/Akt, and Wnt/β-catenin, all of which are closely related to bone metabolism. T-IIA has a dual role in regulating bone formation and bone resorption, making it a potential drug for the treatment of osteoporosis. In addition, T-IIA has neuroprotective, hepatic, renal, cardiac, and cerebral effects, which enhance its therapeutic effect. Despite the remarkable efficacy of T-IIA, its clinical application is limited due to poor solubility and low bioavailability. Recent advances in drug delivery systems, such as liposome formulations and nanocarriers, have improved their pharmacokinetics, increased absorption rate, and bioavailability. Combination therapy with growth factors or stem cells can further enhance its efficacy. Future studies should focus on optimizing the delivery system of T-IIA and exploring its combined application with other therapeutic strategies to expand its clinical application range.
- 5 September 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (9) , 1338
Open AccessPharmacological Effects and Mechanisms of Tanshinone IIA in Bone Injury Repair
Tanshinone IIA (T-IIA), a fat-soluble diterpene quinone extracted from Salvia miltiorrhiza, is widely recognized for its multiple pharmacological properties, including anti-inflammatory, antioxidant, anti-fibrotic, and anti-tumor effects. Recent studies have highlighted its great potential in treating bone metabolic disorders, especially osteoporosis and bone damage repair. Bone health depends on the dynamic balance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption. Disruption of this balance can lead to diseases such as osteoporosis, which is often diagnosed after a fracture, seriously affecting the quality of life and increasing the medical burden. Early identification of high-risk groups and appropriate treatment are essential for preventing fracture recurrence. Studies have shown that T-IIA can promote osteoblast differentiation and inhibit osteoclast activity, targeting key signaling pathways such as NF-κB, PI3K/Akt, and Wnt/β-catenin, all of which are closely related to bone metabolism. T-IIA has a dual role in regulating bone formation and bone resorption, making it a potential drug for the treatment of osteoporosis. In addition, T-IIA has neuroprotective, hepatic, renal, cardiac, and cerebral effects, which enhance its therapeutic effect. Despite the remarkable efficacy of T-IIA, its clinical application is limited due to poor solubility and low bioavailability. Recent advances in drug delivery systems, such as liposome formulations and nanocarriers, have improved their pharmacokinetics, increased absorption rate, and bioavailability. Combination therapy with growth factors or stem cells can further enhance its efficacy. Future studies should focus on optimizing the delivery system of T-IIA and exploring its combined application with other therapeutic strategies to expand its clinical application range.
- Open Access
- 8 August 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (8) , 1174
Research Progress on Icariin Promoting Bone Injury Repair and Regeneration
Icariin (ICA) is a bioactive flavonoid compound extracted from Epimedium plants. In recent years, it has attracted significant research interest in the field of bone tissue repair due to its pharmacological effects via multiple targets and pathways. Studies have shown that ICA promotes the osteogenic differentiation of mesenchymal stem cells (MSCs) and enhances bone matrix formation by regulating signaling pathways such as Akt and Wnt/β-catenin. It concurrently inhibits osteoclast activity to maintain the balance of bone remodeling, thereby simultaneously stimulating new bone regeneration and suppressing bone resorption. At the same time, ICA exerts potent anti-inflammatory and antioxidant effects and promotes angiogenesis, improving the local microenvironment of bone injury and significantly facilitating the regeneration of bone and cartilage tissues. Additionally, ICA exhibits notable protective effects in multiple organ systems including the cardiovascular, hepatic, renal, and nervous systems. Specifically, ICA reduces cardiomyocyte apoptosis and fibrosis to preserve cardiac function, improves hepatic metabolic function and alleviates oxidative stress, attenuates renal inflammation and fibrosis, and—through neuroprotective actions—reduces neuroinflammation and promotes neuronal survival. These multi-organ effects help optimize the systemic environment for bone healing. However, ICA faces significant pharmacokinetic challenges. It has low oral bioavailability (due to poor absorption and extensive first-pass metabolism) as well as a short half-life. Consequently, maintaining effective drug concentrations in vivo is difficult, which limits its therapeutic efficacy and impedes clinical translation. To fully realize its regenerative potential, advanced drug delivery strategies (e.g., nanocarrier-based delivery systems) are being explored to enhance ICA’s bioavailability and prolong its duration of action. Overall, ICA’s multi-modal actions on bone cells, the immune microenvironment, and systemic factors make it a promising multi-target agent for bone regeneration. Addressing its pharmacokinetic limitations through optimized delivery and conducting further clinical studies will be crucial to realize its full therapeutic potential. This review provides a comprehensive overview of recent advances and challenges in translating ICA’s benefits into orthopedic therapy.
- 8 August 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (8) , 1174
Open AccessResearch Progress on Icariin Promoting Bone Injury Repair and Regeneration
Icariin (ICA) is a bioactive flavonoid compound extracted from Epimedium plants. In recent years, it has attracted significant research interest in the field of bone tissue repair due to its pharmacological effects via multiple targets and pathways. Studies have shown that ICA promotes the osteogenic differentiation of mesenchymal stem cells (MSCs) and enhances bone matrix formation by regulating signaling pathways such as Akt and Wnt/β-catenin. It concurrently inhibits osteoclast activity to maintain the balance of bone remodeling, thereby simultaneously stimulating new bone regeneration and suppressing bone resorption. At the same time, ICA exerts potent anti-inflammatory and antioxidant effects and promotes angiogenesis, improving the local microenvironment of bone injury and significantly facilitating the regeneration of bone and cartilage tissues. Additionally, ICA exhibits notable protective effects in multiple organ systems including the cardiovascular, hepatic, renal, and nervous systems. Specifically, ICA reduces cardiomyocyte apoptosis and fibrosis to preserve cardiac function, improves hepatic metabolic function and alleviates oxidative stress, attenuates renal inflammation and fibrosis, and—through neuroprotective actions—reduces neuroinflammation and promotes neuronal survival. These multi-organ effects help optimize the systemic environment for bone healing. However, ICA faces significant pharmacokinetic challenges. It has low oral bioavailability (due to poor absorption and extensive first-pass metabolism) as well as a short half-life. Consequently, maintaining effective drug concentrations in vivo is difficult, which limits its therapeutic efficacy and impedes clinical translation. To fully realize its regenerative potential, advanced drug delivery strategies (e.g., nanocarrier-based delivery systems) are being explored to enhance ICA’s bioavailability and prolong its duration of action. Overall, ICA’s multi-modal actions on bone cells, the immune microenvironment, and systemic factors make it a promising multi-target agent for bone regeneration. Addressing its pharmacokinetic limitations through optimized delivery and conducting further clinical studies will be crucial to realize its full therapeutic potential. This review provides a comprehensive overview of recent advances and challenges in translating ICA’s benefits into orthopedic therapy.
- Open Access
Epimedium-Derived Exosome-Loaded GelMA Hydrogel Enhances MC3T3-E1 Osteogenesis via PI3K/Akt Pathway
Healing large bone defects remains challenging. Gelatin scaffolds are biocompatible and biodegradable, but lack osteoinductive activity. Plant-derived exosomes carry miRNAs, growth factors, and proteins that modulate osteogenesis, but free exosomes suffer from poor stability, limited targeting, and low bioavailability in vivo. We developed a 3D GelMA hydrogel loaded with Epimedium-derived exosomes (“GelMA@Exo”) to improve exosome retention, stability, and sustained release. Its effects on MC3T3-E1 preosteoblasts—including proliferation, osteogenic differentiation, migration, and senescence—were evaluated via in vitro assays. Angiogenic potential was assessed using HUVECs. Underlying mechanisms were examined at transcriptomic and protein levels to elucidate GelMA@Exo’s therapeutic osteogenesis actions. GelMA@Exo exhibited sustained exosome release, enhancing exosome retention and cellular uptake. In vitro, GelMA@Exo markedly boosted MC3T3-E1 proliferation, migration, and mineralized nodule formation, while reducing senescence markers and promoting angiogenesis in HUVECs. Mechanistically, GelMA@Exo upregulated key osteogenic markers (RUNX2, TGF-β1, Osterix, COL1A1, ALPL) and activated the PI3K/Akt pathway. Transcriptomic data confirmed global upregulation of osteogenesis-related genes and bone-regeneration pathways. This study presents a GelMA hydrogel functionalized with plant-derived exosomes, which synergistically provides osteoinductive stimuli and structural support. The GelMA@Exo platform offers a versatile strategy for localized delivery of natural bioactive molecules and a promising approach for bone tissue engineering. Our findings provide strong experimental evidence for the translational potential of plant-derived exosomes in regenerative medicine.
Open AccessEpimedium-Derived Exosome-Loaded GelMA Hydrogel Enhances MC3T3-E1 Osteogenesis via PI3K/Akt Pathway
Healing large bone defects remains challenging. Gelatin scaffolds are biocompatible and biodegradable, but lack osteoinductive activity. Plant-derived exosomes carry miRNAs, growth factors, and proteins that modulate osteogenesis, but free exosomes suffer from poor stability, limited targeting, and low bioavailability in vivo. We developed a 3D GelMA hydrogel loaded with Epimedium-derived exosomes (“GelMA@Exo”) to improve exosome retention, stability, and sustained release. Its effects on MC3T3-E1 preosteoblasts—including proliferation, osteogenic differentiation, migration, and senescence—were evaluated via in vitro assays. Angiogenic potential was assessed using HUVECs. Underlying mechanisms were examined at transcriptomic and protein levels to elucidate GelMA@Exo’s therapeutic osteogenesis actions. GelMA@Exo exhibited sustained exosome release, enhancing exosome retention and cellular uptake. In vitro, GelMA@Exo markedly boosted MC3T3-E1 proliferation, migration, and mineralized nodule formation, while reducing senescence markers and promoting angiogenesis in HUVECs. Mechanistically, GelMA@Exo upregulated key osteogenic markers (RUNX2, TGF-β1, Osterix, COL1A1, ALPL) and activated the PI3K/Akt pathway. Transcriptomic data confirmed global upregulation of osteogenesis-related genes and bone-regeneration pathways. This study presents a GelMA hydrogel functionalized with plant-derived exosomes, which synergistically provides osteoinductive stimuli and structural support. The GelMA@Exo platform offers a versatile strategy for localized delivery of natural bioactive molecules and a promising approach for bone tissue engineering. Our findings provide strong experimental evidence for the translational potential of plant-derived exosomes in regenerative medicine.